Sonoma Pharmaceuticals Secures FDA MoCRA Registration for Microcyn-Based Cosmetic Products, Expanding U.S. Market Access
Reuters
Oct 07
Sonoma Pharmaceuticals Secures FDA MoCRA Registration for Microcyn-Based Cosmetic Products, Expanding U.S. Market Access
**Sonoma Pharmaceuticals Expands U.S. Cosmetic Market Access with FDA MoCRA Registration** BOULDER, COLORADO - Sonoma Pharmaceuticals Inc. (Nasdaq: SNOA), a leading developer of stabilized hypochlorous acid (HOCl) products, announced it has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This regulatory milestone allows Sonoma to manufacture and commercialize its Microcyn technology products as cosmetics in the United States, expanding its reach in the rapidly growing U.S. skincare and dermatology markets. The registration builds on Sonoma's existing FDA medical device establishment registration. No grant or funding was reported; the regulatory approval pertains solely to Sonoma Pharmaceuticals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sonoma Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1082449) on October 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.